<DOC>
	<DOCNO>NCT00733070</DOCNO>
	<brief_summary>A multicenter multinational study evaluate safety efficacy CiTop™ ExPander™ Guidewire cross chronic total occlusion Coronary artery .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CiTop™ ExPander™ Guidewire Crossing Chronic Total Occlusions Coronary Arteries</brief_title>
	<detailed_description />
	<criteria>1 . Informed consent obtain prior trial activity . 2 . Patients , male female 21 80 year age , significant comorbidities ( see exclusion criterion ) . 3 . Patient angiographic document Chronic Total Occlusion show distal TIMI flow 0 1 . 1 . Patient unable give inform consent . 2 . Current participation another study investigational drug device . 3 . Factors make followup and/or repeat angiography difficult unlikely . 4 . Contraindication emergency artery pas surgery . 5 . Lack surgical backup . 6 . Contraindication treatment Aspirin , Clopidogrel and/or Heparin . 7 . Lesion &gt; 40mm length ( calcified lesion adjacent thrombus ) . 8 . Treated vessel reference diameter less 2.5 mm . 9 . Visualization distal lumen less Rentrop Classification Grade 2 collateralization . 10 . Nonvisible entry point target lesion . 11 . Totally occluded bypass graft target vessel . 12 . Acute MI less 1 week procedure . 13 . Patient significant LV dysfunction , 35 % LVEF le . 14 . Patient cancer sever chronic disease life expectance 2 year . 15 . Patient chronic renal failure serum creatinine ≥2 . 16 . Hemoglobin ≤11 . 17 . Patient know suspected tolerate contrast agent . 18 . Morbid Obesity ( BMI &gt; 40 ) . 19 . Drug abuse alcoholism . 20 . Patients custodial care . 21 . Pregnant woman woman childbearing potential positive pregnancy test time procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>CTO</keyword>
	<keyword>Chronic Total Occlusion</keyword>
	<keyword>Revascularization</keyword>
</DOC>